| Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc |
| Journal website http://www.jocmr.org |
Original Article
Volume 10, Number 7, July 2018, pages 601-605
Secondary Salivary Gland Malignancy in Thyroid Cancer: A United States Population Based Study
Tables
| Secondary salivary malignancy | ||||
|---|---|---|---|---|
| Observed | O/E | 95% CI of O/E | Excess risk | |
| CI: confidence interval; O/E: observed to expected ratio; RAI: radioactive iodine. | ||||
| Total Cases | 18 | 3.58 | 2.12 - 5.65 | 0.48 |
| Age | ||||
| < 60 years | 12 | 4.51 | 2.33 - 7.88 | 0.44 |
| ≥ 60 years | 6 | 2.53 | 0.93 - 5.50 | 0.64 |
| Gender | ||||
| Male | 2 | 1.13 | 0.14 - 4.07 | 0.04 |
| Female | 16 | 4.91 | 2.80 - 7.97 | 0.59 |
| Race | ||||
| White | 13 | 3.04 | 1.62 - 5.19 | 0.39 |
| Black | 2 | 5.20 | 0.63 - 18.79 | 0.70 |
| Asian or Pacific Islander | 3 | 9.38 | 1.93 - 27.41 | 1.18 |
| Grade of thyroid malignancy | ||||
| I - well differentiated | 7 | 9.70 | 3.90 - 19.98 | 1.56 |
| II - moderately differentiated | 0 | 0.00 | 0.00 - 19.54 | -0.20 |
| III - poorly differentiated | 1 | 14.52 | 0.37 - 80.88 | 3.56 |
| IV - undifferentiated | 0 | 0.00 | 0.00 - 636.06 | -0.24 |
| Unknown | 10 | 2.47 | 1.18 - 4.54 | 0.27 |
| Radioactive iodine therapy | ||||
| No RAI | 6 | 2.18 | 0.80 - 4.74 | 0.23 |
| RAI | 12 | 5.26 | 2.72 - 9.19 | 0.76 |
| Latency period | ||||
| 2 - 5 months | 1 | 3.94 | 0.10 - 21.97 | 0.49 |
| 6 - 11 months | 3 | 8.25 | 1.70 - 24.10 | 1.21 |
| 12 - 59 months | 9 | 3.82 | 1.75 - 7.25 | 0.50 |
| 60 - 119 months | 5 | 3.11 | 1.01 - 7.25 | 0.42 |
| 120+ months | 0 | 0.00 | 0.00 - 8.18 | -0.22 |
| Primary Salivary Malignancy | Secondary Salivary Malignancy | ||||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Total cases | 19,008 | - | 18 | - | |
| Age at diagnosis | 59.80 ± 18.361) | 53.28 ± 16.634) | P = 0.132 | ||
| Age group | P = 0.07 | ||||
| < 60 years | 8,615 | 45.3% | 12 | 66.7% | |
| ≥ 60 years | 10,393 | 54.7% | 6 | 33.3% | |
| Gender | P < 0.05 | ||||
| Male | 10,240 | 53.9% | 2 | 11.1% | |
| Female | 8,768 | 46.1% | 16 | 88.9% | |
| Race | P = 0.51 | ||||
| White | 15,630 | 82.2% | 13 | 72.2% | |
| Black | 1,656 | 8.7% | 2 | 11.1% | |
| Other | 1,486 | 7.8% | 3 | 16.7% | |
| Unknown | 236 | 1.2% | 0 | 0% | |
| Primary site | P = 0.48 | ||||
| C07.9 - parotid gland | 15,134 | 79.6% | 17 | 94.4% | |
| C08.0 - submandibular gland | 2,845 | 15% | 0 | 0% | |
| C08.1 - sublingual gland | 184 | 1.0% | 0 | 0% | |
| C08.8 - overlapping lesion of major salivary glands | 20 | 0.1% | 0 | 0% | |
| C08.9 - major salivary gland, NOS | 825 | 4.3% | 1 | 5.6% | |
| Grade of salivary cancer | P = 0.08 | ||||
| I - well differentiated | 1,733 | 9.1% | 4 | 22.2% | |
| II - moderately differentiated | 3,337 | 17.5% | 5 | 27.8% | |
| III - poorly differentiated | 3,322 | 17.5% | 1 | 5.6% | |
| IV - undifferentiated | 1,487 | 7.9% | 0 | 0% | |
| Unknown | 9,129 | 48% | 8 | 44.4% | |